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 Neonatal abstinence syndrome (NAS) is a withdrawal syndrome that develops as newborns experience an 
abrupt discontinuation of in utero exposure from abused 
drugs by the mother. With the growing opioid epidemic in 
the United States, NAS is a rapidly growing public health 
concern. Currently, methadone and morphine are the two 
most common pharmacological methods used to treat NAS. 
Methadone requires a longer taper, but can be completed 
at home if the environment is conducive. Morphine on 
the other hand is a faster taper, but must be completed 
in the hospital. Furthermore, iatrogenic administration of 
opioids during treatment may lead to further CNS damage. 
Therefore, physicians aim to limit total drug administration 
while maintaining adequate treatment and ensuring a safe 
transition to home off medications. To hopefully reduce the 
amount of neonatal opioid exposure, the Neonatal Intensive 
Care Unit (NICU) at Lehigh Valley Health Network (LVHN) 
changed the standard NAS treatment from a methadone 
protocol to a morphine based pathway. This project aims 
to compare the hospital length of stay (LOS), days of opioid 
exposure (DOE), and total opioid administration (mg/kg) 
using the two different standards of treatment. 
 
 This project aims to compare the hospital length of stay (LOS), days of opioid exposure (DOE), and total opioid 
administration (mg/kg) using the two different standards of 
treatment.
SMART AIM:  Reduce total days of drug exposure for 
NAS babies admitted to CC NICU from 55 days to less than 
30 days by December 31,2017. 
Balancing AIM:  LOS to not increase more than 30 
days. 
Intervention:  New morphine based NAS protocol 
•  Aim to continue improving quality and efficacy of care while understanding costs 
and constraints of the health care system.
Moving from a methadone to a morphine based protocol  
•  Reached goal of reducing DOE: on average decreased by 32 days (58%)
•  As a result, increased LOS by 17.2 days (167%)
•  Future PDA cycles/ interventions: 
  –  Compliance to pathway non-pharmacological measures
    •  Ex: Increase breast feeding in moms who are not taking other illicit drugs
  –  Compare LOS at LVHM with rooms vs. CC NICU rooms
  –  Weaning faster than q24 for scores <3-4
  –  Nurse re-education with parent/nurse dual scoring
Methodology
 •  Quality improvement project•  Retrospective  and prospective chart review January 
2014- December 2017
•  Included all charts with diagnosis NAS code P 96
•  One PDSA cycle completed
•  Exclusion criteria: 
  –  no treatment with methadone or morphine
  –  incomplete treatment due to medical illness
  –  transfer to outside hospital prior to completion of 
treatment
•  Analyzed averages of methadone and morphine: LOS, 
DOE, and total mg/kg opioid exposure using ANOVA
Chart Review
  
Number of charts flagged with NAS code 112
Number of charts analyzed 74
Number of chsrts excluded* 38
Number of methadone charts 55
Number of morphine charts 19
*exclusion criter = not receiving methadone or morphine, stopping treatment early, 
transfer to outside hospital during treatment. Length of NICU Stay
Days of Exposure to Opioids
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